These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23877785)

  • 41. Tuberculosis screening for long-term care: a cost-effectiveness analysis.
    Verma G; Chuck AW; Jacobs P
    Int J Tuberc Lung Dis; 2013 Sep; 17(9):1170-7. PubMed ID: 23928166
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Risk of tuberculosis in healthcare workers: risk assessment and medical surveillance].
    Magrini A; Coppeta L; Somma G; Neri A; Gentili S; Fiocco G; Pietroiusti A
    Ig Sanita Pubbl; 2016; 72(2):137-43. PubMed ID: 27336958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness analysis of interferon-γ release assays versus chest X-ray for annual tuberculosis screening of healthcare workers.
    Kowada A; Deshpande GA; Takahashi O; Shimbo T; Fukui T
    J Hosp Infect; 2011 Jun; 78(2):152-4. PubMed ID: 21440954
    [No Abstract]   [Full Text] [Related]  

  • 44. The frequency of tuberculosis chemoprophylaxis prior to TNF-α inhibitor treatment, and the incidence tuberculosis infection using a two-step screening algorithm for latent tuberculosis infection: data from the BioRx.si registry.
    Tomsic M; Rotar Z
    Ann Rheum Dis; 2012 Nov; 71(11):1909-11. PubMed ID: 22805974
    [No Abstract]   [Full Text] [Related]  

  • 45. From latent to patent: rethinking prediction of tuberculosis.
    Cobelens F; Kik S; Esmail H; Cirillo DM; Lienhardt C; Matteelli A
    Lancet Respir Med; 2017 Apr; 5(4):243-244. PubMed ID: 28017341
    [No Abstract]   [Full Text] [Related]  

  • 46. Impact of interferon-γ release assay on the latent tuberculosis cascade of care: a population-based study.
    Roth DZ; Ronald LA; Ling D; Chiang LY; Cook VJ; Morshed MG; Johnston JC
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331032
    [No Abstract]   [Full Text] [Related]  

  • 47. [Latent M. tuberculosis infection, update 2011].
    Lechartier B; Mazza-Stalder J; Janssens JP; Nicod LP
    Rev Med Suisse; 2011 Nov; 7(318):2289-94. PubMed ID: 22400364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis.
    Diel R; Wrighton-Smith P; Zellweger JP
    Eur Respir J; 2007 Aug; 30(2):321-32. PubMed ID: 17504793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Who must have tuberculosis screening? Characteristics of risk patients].
    MMW Fortschr Med; 2013 May; 155(9):16-8. PubMed ID: 23951641
    [No Abstract]   [Full Text] [Related]  

  • 50. Diagnosis of Latent Tuberculosis Infection: Too Soon to Pull the Plug on the Tuberculin Skin Test.
    Collins LF; Geadas C; Ellner JJ
    Ann Intern Med; 2016 Jan; 164(2):122-4. PubMed ID: 26642354
    [No Abstract]   [Full Text] [Related]  

  • 51. Immigration screening for latent tuberculosis infection.
    Denholm JT
    Med J Aust; 2013 Jun; 198(10):524. PubMed ID: 23725254
    [No Abstract]   [Full Text] [Related]  

  • 52. Contact tracing in low-incidence tuberculosis settings.
    van Leth F; Borgdorff M
    Int J Tuberc Lung Dis; 2011 Dec; 15(12):1566. PubMed ID: 22118163
    [No Abstract]   [Full Text] [Related]  

  • 53. Prebiologic Therapy Tuberculosis Screening Experience in a Pediatric Rheumatology Center: TST and IGRA Are Both Necessary.
    Marino A; Chiappini E; Cimaz R; Simonini G
    Pediatr Infect Dis J; 2017 Apr; 36(4):440-441. PubMed ID: 28288085
    [No Abstract]   [Full Text] [Related]  

  • 54. Re: "Prebiologic Therapy Tuberculosis Screening Experience in a Pediatric Rheumatology Center: TST and IGRA Are Both Necessary".
    Lowenthal P; Barry PM; Flood J
    Pediatr Infect Dis J; 2017 Apr; 36(4):441. PubMed ID: 28288086
    [No Abstract]   [Full Text] [Related]  

  • 55. Re: Interferon-gamma release assay agreement with tuberculin skin test in pretransplant screening for latent tuberculosis in a high-prevalence country.
    Nassiri AA; Tabarsi P
    Iran J Kidney Dis; 2014 Sep; 8(5):432-3. PubMed ID: 25194415
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost effectiveness of high resolution computed tomography with interferon-gamma release assay for tuberculosis contact investigation.
    Kowada A
    Eur J Radiol; 2013 Aug; 82(8):1353-8. PubMed ID: 23489981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Latent Tuberculosis Infection Screening and 2-Year Outcome in Antiretroviral-Naive HIV-Infected Patients in a Low-Prevalence Country.
    Bourgarit A; Baron G; Breton G; Tattevin P; Katlama C; Allavena C; Campa P; Ravaud P; Lortholary O; Carcelain G;
    Ann Am Thorac Soc; 2015 Aug; 12(8):1138-45. PubMed ID: 26213798
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current approach to latent tuberculosis diagnosis and treatment among medical center occupational health physicians.
    Vinnard C; Linkin D; Behrman A
    Infect Control Hosp Epidemiol; 2012 Dec; 33(12):1262-5. PubMed ID: 23143368
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An evaluation of the use of a negative interferon-γ release assay for tuberculosis screening before TNF antagonist therapy.
    Woodfield G; Passey-Heaton B; Chakrabarti A; Pozniak A; Loebinger MR
    Eur Respir J; 2014 Nov; 44(5):1369-72. PubMed ID: 25186258
    [No Abstract]   [Full Text] [Related]  

  • 60. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany.
    Diel R; Nienhaus A; Loddenkemper R
    Chest; 2007 May; 131(5):1424-34. PubMed ID: 17494792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.